SCHEMBL4919937

SCHEMBL4919937

CC(C)(C)C[PH](=O)N(c1ccccc1)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.39
MEN1 O00255 3/20 0.39
CYP2C19 P33261 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
ESR1 P03372 1/20 0.35
HTT P42858 2/20 0.34
ALDH1A1 P00352 6/20 0.34
TSHR P16473 3/20 0.34
GLA P06280 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.32
CA12 O43570 1/20 0.32
CA2 P00918 1/20 0.32
CA9 Q16790 1/20 0.32
NPSR1 Q6W5P4 2/20 0.31
ALOX15 P16050 1/20 0.31
TP53 P04637 2/20 0.31
NPC1 O15118 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4915223 0.73 TSHR (0.42) KMT2AMEN1SMN1; SMN2CYP3A4HTT
SCHEMBL4924726 0.68 GAA (0.34) KMT2AMEN1CYP2C19SMN1; SMN2CYP3A4
SCHEMBL27701245 0.64 ALDH1A1 (0.44) KMT2AMEN1CYP2C19CYP3A4CYP2C9
SCHEMBL8432372 0.64 NPSR1 (0.44) KMT2AMEN1CYP2C19SMN1; SMN2CYP3A4
SCHEMBL2056786 0.63 MEN1 (0.40) KMT2AMEN1CYP2C19SMN1; SMN2CYP3A4
SCHEMBL8767323 0.63 TSHR (0.50) KMT2AMEN1CYP2C19SMN1; SMN2CYP3A4
SCHEMBL13259855 0.63 ESR1 (0.43) KMT2AMEN1CYP2C19SMN1; SMN2CYP3A4
SCHEMBL29027385 0.61 MEN1 (0.36) KMT2AMEN1CYP2C19SMN1; SMN2CYP3A4
SCHEMBL139849 0.61 MEN1 (0.39) KMT2AMEN1CYP2C19SMN1; SMN2CYP3A4
SCHEMBL10159871 0.61 CA12 (0.44) KMT2AMEN1CYP2C19SMN1; SMN2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8471067-B2 Stereoselective preparation of P-chiral four-co-ordinated phosphorus compound (o-Tolylphenylmethylphosphine oxide) by reacting chiral alcohol, chiral amine or chiral thiol, with P-chiral three-co-ordinated phosphorus compound, in presence of electrophile UNIVERSITY COLLEGE DUBLIN (IE) 2013-06-25 US disclosed
US-20080255391-A1 Chiral Phosphorus Compounds UNIVERSITY COLLEGE DUBLIN NATIONAL UNIVERSITY OF IRELAND (IE) 2008-10-16 US disclosed
EP-1751170-A1 CHIRAL PHOSPHORUS COMPOUNDS UNIVERSITY COLLEGE DUBLIN (IE) 2007-02-14 EP disclosed
WO-2005118603-A1 CHIRAL PHOSPHORUS COMPOUNDS UNIVERSITY COLLEGE DUBLIN (IE) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255391-A1 Chiral Phosphorus Compounds PHOSPHO1, PNKP, PTMS KMT2A 3836/4885MEN1 3668/4885CYP2C19 1337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.